logo
logo

Genecentric Therapeutics Closes $7.5 Million Series B1 Financing

Nov 08, 2021almost 4 years ago

Amount Raised

$7.5 Million

DurhamBiotechnology

Description

GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, today announced the closing of an oversubscribed Series B1 financing, which raised $7.5 million.

Company Information

Company

GeneCentric Therapeutics

Location

100 CAPITOLA DRIVE

Durham, North Carolina, United States

About

GeneCentric is a precision oncology company transforming cancer diagnostics and genomic profiling through the power of gene expression. With a foundation built on over a decade of research into gene expression, including the PurIST® test (commercially available through Tempus), GeneCentric has pioneered ExpressCT™, a proprietary technology that enables gene expression inference directly from circulating tumor DNA (ctDNA). This innovation is embodied in the GenomicsNext™ platform, a multimodal liquid biopsy solution that simultaneously detects DNA alterations and inferred gene expression from a single blood sample.

Related People